These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

783 related articles for article (PubMed ID: 34013272)

  • 1. Infection and vaccine-induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant.
    Edara VV; Lai L; Sahoo MK; Floyd K; Sibai M; Solis D; Flowers MW; Hussaini L; Ciric CR; Bechnack S; Stephens K; Mokhtari EB; Mudvari P; Creanga A; Pegu A; Derrien-Colemyn A; Henry AR; Gagne M; Graham BS; Wrammert J; Douek DC; Boritz E; Pinsky BA; Suthar MS
    bioRxiv; 2021 May; ():. PubMed ID: 34013272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant.
    Edara VV; Norwood C; Floyd K; Lai L; Davis-Gardner ME; Hudson WH; Mantus G; Nyhoff LE; Adelman MW; Fineman R; Patel S; Byram R; Gomes DN; Michael G; Abdullahi H; Beydoun N; Panganiban B; McNair N; Hellmeister K; Pitts J; Winters J; Kleinhenz J; Usher J; O'Keefe JB; Piantadosi A; Waggoner JJ; Babiker A; Stephens DS; Anderson EJ; Edupuganti S; Rouphael N; Ahmed R; Wrammert J; Suthar MS
    Cell Host Microbe; 2021 Apr; 29(4):516-521.e3. PubMed ID: 33798491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infection and mRNA-1273 vaccine antibodies neutralize SARS-CoV-2 UK variant.
    Edara VV; Floyd K; Lai L; Gardner M; Hudson W; Piantadosi A; Waggoner JJ; Babiker A; Ahmed R; Xie X; Lokugamage K; Menachery V; Shi PY; Suthar MS
    medRxiv; 2021 Feb; ():. PubMed ID: 33564782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced binding and neutralization of infection- and vaccine-induced antibodies to the B.1.351 (South African) SARS-CoV-2 variant.
    Edara VV; Norwood C; Floyd K; Lai L; Davis-Gardner ME; Hudson WH; Mantus G; Nyhoff LE; Adelman MW; Fineman R; Patel S; Byram R; Gomes DN; Michael G; Abdullahi H; Beydoun N; Panganiban B; McNair N; Hellmeister K; Pitts J; Winters J; Kleinhenz J; Usher J; O'Keefe JB; Piantadosi A; Waggoner JJ; Babiker A; Stephens DS; Anderson EJ; Edupuganti S; Rouphael N; Ahmed R; Wrammert J; Suthar MS
    bioRxiv; 2021 Feb; ():. PubMed ID: 33655254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants.
    Wu K; Werner AP; Moliva JI; Koch M; Choi A; Stewart-Jones GBE; Bennett H; Boyoglu-Barnum S; Shi W; Graham BS; Carfi A; Corbett KS; Seder RA; Edwards DK
    bioRxiv; 2021 Jan; ():. PubMed ID: 33501442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 Omicron variant.
    Edara VV; Manning KE; Ellis M; Lai L; Moore KM; Foster SL; Floyd K; Davis-Gardner ME; Mantus G; Nyhoff LE; Bechnak S; Alaaeddine G; Naji A; Samaha H; Lee M; Bristow L; Hussaini L; Ciric CR; Nguyen PV; Gagne M; Roberts-Torres J; Henry AR; Godbole S; Grakoui A; Sexton M; Piantadosi A; Waggoner JJ; Douek DC; Anderson EJ; Rouphael N; Wrammert J; Suthar MS
    bioRxiv; 2021 Dec; ():. PubMed ID: 34981056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cross-neutralization of SARS-CoV-2 B.1.1.7 and P.1 variants in vaccinated, convalescent and P.1 infected.
    Gidari A; Sabbatini S; Bastianelli S; Pierucci S; Busti C; Monari C; Luciani Pasqua B; Dragoni F; Schiaroli E; Zazzi M; Francisci D
    J Infect; 2021 Oct; 83(4):467-472. PubMed ID: 34320390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-COV-2 Delta variant displays moderate resistance to neutralizing antibodies and spike protein properties of higher soluble ACE2 sensitivity, enhanced cleavage and fusogenic activity.
    Neerukonda SN; Vassell R; Lusvarghi S; Wang R; Echegaray F; Bentley L; Eakin AE; Erlandson KJ; Katzelnick LC; Weiss CD; Wang W
    bioRxiv; 2021 Nov; ():. PubMed ID: 34790980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutralization of viruses with European, South African, and United States SARS-CoV-2 variant spike proteins by convalescent sera and BNT162b2 mRNA vaccine-elicited antibodies.
    Tada T; Dcosta BM; Samanovic-Golden M; Herati RS; Cornelius A; Mulligan MJ; Landau NR
    bioRxiv; 2021 Feb; ():. PubMed ID: 33564768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral Spike vaccines.
    Shen X; Tang H; McDanal C; Wagh K; Fischer W; Theiler J; Yoon H; Li D; Haynes BF; Sanders KO; Gnanakaran S; Hengartner N; Pajon R; Smith G; Dubovsky F; Glenn GM; Korber B; Montefiori DC
    bioRxiv; 2021 Jan; ():. PubMed ID: 33532764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Will vaccine-derived protective immunity curtail COVID-19 variants in the US?
    Mancuso M; Eikenberry SE; Gumel AB
    Infect Dis Model; 2021; 6():1110-1134. PubMed ID: 34518808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heterologous immunization with Covishield and Pfizer vaccines against SARS-CoV-2 elicits a robust humoral immune response.
    Ostadgavahi AT; Booth R; Sisson G; McMullen N; Warhuus M; Robertson P; Miller M; Allen WC; El Sherif M; Brownlie R; Falzarano D; Richardson CD
    J Infect Dev Ctries; 2021 May; 15(5):653-656. PubMed ID: 34106888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low Neutralizing Antibody Titers against the Mu Variant of SARS-CoV-2 in 31 BNT162b2 Vaccinated Individuals in Colombia.
    Álvarez-Díaz DA; Muñoz AL; Tavera-Rodríguez P; Herrera-Sepúlveda MT; Ruiz-Moreno HA; Laiton-Donato K; Franco-Muñoz C; Pelaez-Carvajal D; Cuellar D; Muñoz-Suarez AM; Galindo M; Arias-Ramírez EJ; Mercado-Reyes M
    Vaccines (Basel); 2022 Jan; 10(2):. PubMed ID: 35214639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Omicron mutations enhance infectivity and reduce antibody neutralization of SARS-CoV-2 virus-like particles.
    Syed AM; Ciling A; Khalid MM; Sreekumar B; Chen PY; Kumar GR; Silva I; Milbes B; Kojima N; Hess V; Shacreaw M; Lopez L; Brobeck M; Turner F; Spraggon L; Taha TY; Tabata T; Chen IP; Ott M; Doudna JA
    medRxiv; 2022 Jan; ():. PubMed ID: 34981067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma neutralization properties of the SARS-CoV-2 Omicron variant.
    Schmidt F; Muecksch F; Weisblum Y; Da Silva J; Bednarski E; Cho A; Wang Z; Gaebler C; Caskey M; Nussenzweig MC; Hatziioannou T; Bieniasz PD
    medRxiv; 2021 Dec; ():. PubMed ID: 34931199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cross-Neutralizing Activity Against SARS-CoV-2 Variants in COVID-19 Patients: Comparison of 4 Waves of the Pandemic in Japan.
    Furukawa K; Tjan LH; Sutandhio S; Kurahashi Y; Iwata S; Tohma Y; Sano S; Nakamura S; Nishimura M; Arii J; Kiriu T; Yamamoto M; Nagano T; Nishimura Y; Mori Y
    Open Forum Infect Dis; 2021 Oct; 8(10):ofab430. PubMed ID: 34631915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Partial resistance of SARS-CoV-2 Delta variants to vaccine-elicited antibodies and convalescent sera.
    Tada T; Zhou H; Dcosta BM; Samanovic MI; Mulligan MJ; Landau NR
    iScience; 2021 Nov; 24(11):103341. PubMed ID: 34723159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice.
    Wu K; Choi A; Koch M; Elbashir S; Ma L; Lee D; Woods A; Henry C; Palandjian C; Hill A; Jani H; Quinones J; Nunna N; Oâ Connell S; McDermott AB; Falcone S; Narayanan E; Colpitts T; Bennett H; Corbett KS; Seder R; Graham BS; Stewart-Jones GB; Carfi A; Edwards DK
    bioRxiv; 2021 Oct; ():. PubMed ID: 33880468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. mRNA Vaccines Enhance Neutralizing Immunity against SARS-CoV-2 Variants in Convalescent and ChAdOx1-Primed Subjects.
    Fabricius D; Ludwig C; Scholz J; Rode I; Tsamadou C; Jacobsen EM; Winkelmann M; Grempels A; Lotfi R; Janda A; Körper S; Adler G; Debatin KM; Schrezenmeier H; Jahrsdörfer B
    Vaccines (Basel); 2021 Aug; 9(8):. PubMed ID: 34452043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.